Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

Upon final analysis, there was significant benefit for SG in patients with the two highest quartiles of TROP2 expression (220–275 and 275–300), The interaction between treatment and continuous TROP2 expression for OS was marginally significant (range, P = 0.04–0.05), and the interaction between treatment and TROP2 H -score expression by quartiles for OS was trending toward significance ( P = 0.054).

also in 4,485 other papers

Upon final analysis, there was significant benefit for SG in patients with the two highest quartiles of TROP2 expression (220–275 and 275–300), The interaction between treatment and continuous TROP2 expression for OS was marginally significant (range, P = 0.04–0.05), and the interaction between treatment and TROP2 H -score expression by quartiles for OS was trending toward significance ( P = 0.054).

also in 131 other papers

Therapeutic targets, such as FAK and PARP, were enriched in responding models, whereas resistant tumors were enriched for mesenchymal features, including lower E-cadherin and higher caveolin and AXL; however, these differences did not reach statistical significance when controlled for multiple testing (Supplementary Table S11).

also in 20,614 other papers